Myeloproliferative diseases — a rare hematological pathology, the main manifestation of which are thrombotic complications, in particular stroke.

OBJECTIVE

To perform clinical and instrumental evaluation of several aspects of cerebrovascular disorder as well as to study the role of driver mutations and their contribution to the realization of thrombotic cerebral events in patients with myeloproliferative diseases.

MATERIALS AND METHODS

The study included 152 patients with an established «myeloproliferative disease» diagnosis. Clinical and instrumental study was carried out to identify the signs of ischemic stroke history (ischemic damage of brain substance) in patients with myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis), and the role of driver mutations and their contribution to the realization of thrombotic cerebral events were assessed.

RESULTS

Traditional vascular risk predictors (arterial hypertension, carotid atherosclerosis, age, diabetes mellitus, myocardial infarction) have not been independent factors associated with history of ischemic stroke in the multivariate logistic regression model. Independent factors associated with stroke in patients of this cohort were male sex, presence of mutation in the CALR gene, history of venous thrombosis.

CONCLUSION

In patients with myeloproliferative diseases, according to the results of the study, a different pattern of risk factors for cerebral thrombosis is determined from the traditional one, which must be taken into account when managing this category of patients and prescribing preventive therapy.